Cryoport Systems Announces Major Expansion of Pont-du-Château Facility and Official Rebrandring of Cell&Co
13 Jun. 2024
News
Read also...
This development increases the facility’s size from 445 m² to 1040 m², enhancing its BioServices and biostorage capabilities. Concurrently, this expansion marks the official rebrand of Cell&Co BioServices to Cryoport Systems, solidifying its integration into Cryoport’s global operations.
Cryoport Systems continues to expand its reach across Europe, bringing its world-class temperature-controlled supply chain solutions closer to the rapidly growing market for advanced therapies. Our growing footprint is Enabling the Outcome™ for biopharmaceutical research and development across Europe, supporting the delivery of critical therapies from initial research to global commercialization. By expanding our presence, we provide additional services and capacity straight to the heart of Europe, supporting the rapid growth of advanced therapies in the region.
The expanded facility now supports a broader range of services, significantly boosting its storage capacity and operational capabilities:
This expansion also marks the official rebranding of Cell&Co BioServices as Cryoport Systems. Acquired in April 2022, Cell&Co has been a pivotal part of Cryoport Systems’ growth in the EMEA region. This rebrand aligns with Cryoport Systems’ strategic vision and reinforces its global presence.
“We are thrilled to announce the expansion of our Pont-du-Château facility and the official rebranding of Cell&Co,” said Mark Sawicki, CEO of Cryoport Systems. “These advancements reflect our dedication to providing the highest standards of service and innovation in temperature-controlled supply chain solutions. The enhanced capabilities of the Pont-du-Château site position us to better serve the life sciences industry and support the development and delivery of critical therapies worldwide.”
The expanded Pont-du-Château facility continues to deliver comprehensive GMP biorepository services, clinical trial supply services (including importation, QP services, secure storage, drug packaging and labelling, and distribution), and commercial supply services. This expansion enhances Cryoport Systems’ ability to support the pharmaceutical and biotech industries with high-quality BioServices, reflecting our commitment to advancing the growing market for advanced therapies across Europe.
Cryoport Systems is strategically expanding its European presence with our established facilities in The Netherlands and multiple locations in France, including Clermont-Ferrand and the newly expanded Pont-du-Château facility. Additionally, we will soon launch a Global Supply Chain Hub in Stevenage, UK, and a Cryopreservation Center in Villers-le-Bouillet, Belgium.
Copyright © 2019 - Legal notice - Cookie management